GPP Announces Growth Recapitalization of Alliance Biomedical Research

Alliance Biomedical Research pic

Alliance Biomedical Research

Founded in 2003, Great Point Partners is a healthcare investment firm with. Based in Greenwich, Connecticut, Great Point Partners (GPP) has a team of 28 professionals investing primarily in North America and additionally in Western Europe.

In September 2016, GPP announced a growth recapitalization of Alliance Biomedical Research (ABR), a clinical trial research business based in Greenville, South Carolina. Pharmaceutical and biotechnology companies contract with ABR to conduct Phase II through Phase IV clinical studies, which involves recruiting eligible patients to test drugs, monitoring results, complying with FDA and sponsor standards, and giving an account of their results to the clients.

Founded in 2004 with a vision of becoming the leading clinical trial research company, ABR has been able to grow organically from a single location to 11 sites. GPP’s investment will enable ABR to improve its infrastructure and execute a growth strategy comprising the development of new facilities and strategic tuck-in acquisitions.

With the new partnership, Jim Petrilla, founder of BioAgilytix, will join ABR as the new chief executive officer and Richard Vaillant, former CFO at Cytovance Biologics, will be ABR’s new CFO.